Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

51 results about "Rat Sarcoma" patented technology

Histiocytic sarcoma is the most frequent hematopoietic tumor in rats. We report here a histiocytic sarcoma infiltrating the liver, the spleen and the pancreas from a Wistar rat. In the liver, the tumor was associated with oval cell and bile duct hyperplasia.

Small molecule inhibitors of KRAS g12d mutant

Compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Owner:MERCK SHARP & DOHME LLC

Small molecule protein degraders of KRAS g12d mutant

Compounds or their pharmaceutically acceptable salts can modulate the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Owner:MERCK SHARP & DOHME LLC

Small molecule inhibitors of KRAS proteins

Compounds of Formulae (I)-(VII) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and / or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formulae (I)-(VII) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Owner:MERCK SHARP & DOHME LLC

Heterobifunctional compounds for the degradation of KRAS protein

PCT designated stage expiredWO2025006753A2Organic active ingredientsOrganic chemistryViral OncogeneRat sarcoma virus
The invention provides compounds that degrade the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein including mutant forms via the ubiquitination of the KRAS protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
Owner:MERCK PATENT GMBH +2

Heterobifunctional compounds for the degradation of kras

PCT designated stage expiredWO2025006783A2Organic active ingredientsOrganic chemistryViral OncogeneRat sarcoma virus
The invention provides compounds that degrade the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein including mutant forms via the ubiquitination of the KRAS protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
Owner:ANDERSON COREY DON +3

Pharmaceutical composition containing PRMT5 inhibitor and kras g12c inhibitor

PCT designated stageWO2025157289A1Antineoplastic agentsPharmaceutical active ingredientsViral OncogeneDisease
A pharmaceutical composition comprising a protein arginine methyltransferase 5 (PRMT5) inhibitor and a KRASG12C (Kirsten rat sarcoma viral oncogene homolog glycine-to-cysteine) inhibitor. The pharmaceutical composition can be used for treating various cancers, comprising solid tumors. The combined product can be used for treating any number of diseases associated with PRMT5 and / or KRASG12C.
Owner:SHANGHAI APEIRON THERAPEUTICS CO LTD

Small molecule inhibitors of KRAS g12c mutant

Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Owner:MERCK SHARP & DOHME LLC

Small molecule protein degraders of KRAS g12d mutant

Compounds disclosed herein or their pharmaceutically acceptable salts can modulate the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Owner:MERCK SHARP & DOHME LLC

Small molecule inhibitors of KRAS proteins

Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and / or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Owner:MERCK SHARP & DOHME LLC

Small molecule inhibitors of KRAS proteins

Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and / or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Owner:MERCK SHARP & DOHME LLC

Small molecule inhibitors of KRAS proteins

Compounds of Formulae (I)-(VII) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and / or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formulae (I)-(VII) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Owner:MERCK SHARP & DOHME LLC

Small molecule protein degraders of KRAS g12d mutant

Compounds or their pharmaceutically acceptable salts can modulate the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Owner:MERCK SHARP & DOHME LLC

Protein degraders of KRAS g12d mutant

Compounds or their pharmaceutically acceptable salts can modulate the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Owner:MERCK SHARP & DOHME LLC

Novel compounds as KRAS inhibitors and uses thereof

PCT designated stageWO2025261393A1Organic active ingredientsOrganic chemistryViral OncogeneDisease
Described herein are Kirsten rat sarcoma viral oncogene homologue (KRAS) inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of a KRAS associated disease or disorder.
Owner:INSILICO MEDICINE IP LTD

Anti-mutated KRAS t cell receptors

Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for an HLA-A11-restricted epitope of mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) (KRAS7-16), Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS), or Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS). Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

HLA class II-restricted t cell receptors against mutated RAS

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

Neoantigen peptide mimics

Disclosed herein are polypeptide fragments and polynucleotides based on mutant capicua transcriptional repressor (CIC), catenin beta 1 (CTNNB1), v-erb-b2 erythroblastic leukemia viral oncogene homolog B (ERBB2), kirsten rat sarcoma (KRAS), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), phosphatase and tensin homolog (PTEN), splicing factor 3b subunit 1 (SF3B1), SRY-box transcription factor 17 (SOX17), tumor protein 53 (TP53), and cytomegalovirus (CMV) sequences, vectors, host cells, viruses, methods for generating CD8+ T-cells, and methods of treatment. Also disclosed herein are T-cell receptors (TCRs), polynucleotides, vectors and cells comprising the TCRs, and methods of treatment.
Owner:JANSSEN BIOTECH INC

Small molecule inhibitors of KRAS proteins

Compounds of Formulae (I)-(VII) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and / or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formulae (I)-(VII) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Owner:MERCK SHARP & DOHME CORP +1

CDK2 inhibitor for the treatment of KRAS mutant cancer

PCT designated stageWO2026064479A1Amine active ingredientsHeterocyclic compound active ingredientsAcquired resistanceCyclin-dependent kinase 2
Combinations, compositions and uses of a cyclin dependent kinase 2 (CDK2) inhibitor INX-315, or a pharmaceutically acceptable salt thereof described herein, in combination with a CDK4 / 6 inhibitor for the treatment of disorders characterized by mutation of Kirsten rat sarcoma (KRAS), including but not limited to the treatment of tumors and cancers. In addition, the invention includes a method to delay acquired resistance to a RAS inhibitors in a KRAS mutant cancer, comprising administering the CDK2 inhibitor INX-315 optionally in combination or alternation with a KRAS inhibitor.
Owner:INCYCLIX BIO LLC

Small molecule inhibitors of mutant KRAS proteins

The compound of formula (I) or its pharmaceutically acceptable salt can inhibit the G12C, G12D and / or G12V mutant forms of Kirsten rat sarcoma (KRAS) protein, and is expected to have utility as a therapeutic agent, for example, for treating cancer.The present disclosure also provides a pharmaceutical composition comprising the compound of formula (I) or its pharmaceutically acceptable salt.The present disclosure also relates to the method for the use of the compound or its pharmaceutically acceptable salt in the treatment and prevention of cancer, and the method for preparing a medicament for this purpose.
Owner:MERCK SHARP & DOHME LLC +2

Small molecule inhibitors of KRAS mutated proteins

Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D and / or G12V mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Owner:MERCK SHARP & DOHME LLC +2

Small molecule inhibitors of KRAS protein

Compounds of formulae (I) to (VII) or pharmaceutically acceptable salts thereof inhibit G12C, G12D, G12V and / or G13D mutants of the Kirsteen rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, e.g., in the treatment of cancer. The present disclosure also provides pharmaceutical compositions comprising compounds of Formulae (I) to (VII) or pharmaceutically acceptable salts thereof. The present disclosure also relates to methods of using these compounds, or pharmaceutically acceptable salts thereof, in the treatment and prevention of cancer and in the preparation of medicaments for this purpose.
Owner:默沙东有限责任公司

Spirocyclic-substituted 6,7-dihydro-pyrano[2,3- d]pyrimidine inhibitors of KRAS G12C mutant

The disclosure provides compounds of Formula (I)or a pharmaceutically acceptable salt thereof, wherein W1, W2, Y, Z, CS, R2, and R3 are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Owner:MERCK SHARP & DOHME LLC

TCR recognizing g12v mutated ras and uses thereof

The invention relates to a selection of verified targets for T-cell receptors (TCR) against mutated human rat sarcoma (RAS) peptides as well as to several new T-cell receptors (TCR), which are isolated and / or expressed in an engineered cell, and which specifically recognize a G12V mutated human rat sarcoma (RAS) peptide, wherein the peptide is a mutated human Kirsten RAS (KRAS) peptide, a mutated human Harvey RAS (HRAS) peptide, or a human neuroblastoma RAS (NRAS) peptide, which consists of VVVGAVGVGK (SEQ ID NO: 1) or VVGAVGVGK (SEQ ID NO:2) presented in a HLA- A*11 complex, and wherein the individual TCR comprises a paired TCR alpha- and TCR beta-chain. The invention further relates to engineered cells and vectors expressing said TCRs and medical uses of the same for treating cancer patients.
Owner:GENOVIE

Small molecule inhibitors of KRAS proteins

Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and / or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Owner:MERCK SHARP & DOHME LLC

TCR recognizing g12v mutated ras and uses thereof

The invention relates to a selection of verified targets for T-cell receptors (TCR) against mutated human rat sarcoma (RAS) peptides as well as to several new T-cell receptors (TCR), which are isolated and / or expressed in an engineered cell, and which specifically recognize a G12V mutated human rat sarcoma (RAS) peptide, wherein the peptide is a mutated human Kirsten RAS (KRAS) peptide, a mutated human Harvey RAS (HRAS) peptide, or a human neuroblastoma RAS (NRAS) peptide, which consists of VVVGAVGVGK (SEQ ID NO: 1) or VVGAVGVGK (SEQ ID NO:2) presented in a HLA- A*11 complex, and wherein the individual TCR comprises a paired TCR alpha- and TCR beta-chain. The invention further relates to engineered cells and vectors expressing said TCRs and medical uses of the same for treating cancer patients.
Owner:GENOVIE

Proteolysis modulators and related methods of use

The invention relates to modulators of proteolysis and related methods of use. The present disclosure relates to bifunctional compounds that are useful as modulators of Kirsteen rat sarcoma proteins (target proteins). In particular, the present disclosure relates to bifunctional compounds having one end containing a Von Hippel-Lindau, cerebron, an apoptotic protein inhibitor or a mouse double minute 2 homolog ligand that binds to the respective E3 ubiquitin ligase and the other end containing a moiety that binds to a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of the target protein. The present disclosure exhibits a broad range of pharmacological activities related to degradation / inhibition of a target protein. Treatment or prevention of diseases or conditions caused by aggregation, accumulation and / or overactivity of target proteins with the compounds and compositions of the invention.
Owner:ARVINAS OPERATIONS INC +1

Small molecule inhibitors of KRAS g12d mutant

Compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
Owner:MERCK SHARP & DOHME LLC

Methods of using Anti-EGF antibodies to augment the activity of BRAF and KRAS inhibitors

Embodiments of the present disclosure are directed to methods for treating and preventing disease conditions, such as cancer, particularly in those individuals who have developed a resistance to, or who are not responsive to, cancer therapies involving v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) or Kirsten rat sarcoma oncogene homolog (KRAS) inhibitors.
Owner:IN3BIO LTD